Press Releases

Notification and public disclosure of transactions by PDMR and persons closely associated with them

By August 22, 2016No Comments

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 22 August 2016 it was notified that Amphion Innovations plc (“Amphion”) had pledged an additional 11,655,480 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion’s loan facility (the “Share Pledge”).  In total, Amphion has pledged 27,961,625 ordinary shares in the Company in relation to the Share Pledge.  As a result of the Share Pledge, Amphion will transfer legal title to but will retain the beneficial interest in these pledged ordinary shares. Richard Morgan and Robert Bertoldi, non-executive Chairman and executive director of the Company respectively, are also directors of Amphion (the “Amphion Directors”). Amphion is therefore a “Person Closely Associated” with the Amphion Directors under the Market Abuse Regulation.

The Share Pledge does not change the number of ordinary shares of the Company in issue.

Company Contacts

Motif Bio plc

Graham Lumsden, Chief Executive Officer
info@motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Giles Balleny
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners Limited (Broker)

Patrick Claridge / David Hignell
John Howes / Rob Rees (Broking)
+44 (0) 207 382 1100

Walbrook PR Ltd. (Public and Investor Relations)

Paul McManus / Mike Wort
Main: +44 (0)20 7933 8780
Paul: +44 (0)7980 541 893
Mike: +44 (0)7900 608 002
motifbio@walbrookpr.com

MC Services AG (European IR)

Raimund Gabriel
+49 (0) 89 210 2280